Nephrology
JINARC®(tolvaptan tablets)
- Aquaretic
- Selective vasopressin V2-receptor antagonist
- It is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease.
- For more product information, you may visit:https://jinarchk.com/
- For more disease information, you may refer to below website:http://hkadpkd.com/
| Formulation | Dosage | Colour / Appearance |
|---|---|---|
| Oral Tablets | 15 mg | Blue, triangular, shallow-convex, debossed with “OTSUKA” and “15” on one side |
| 30 mg | Blue, round, shallow-convex, debossed with “OTSUKA” and “30” on one side |
|
| 45 mg | Blue, square, shallow-convex, debossed with “OTSUKA” and “45” on one side |
|
| 60 mg | Blue, modified rectangular, shallow-convex, debossed with “OTSUKA” and “60” on one side |
|
| 90 mg | Blue, pentagonal, shallow-convex, debossed with “OTSUKA” and “90” on one side |
Package:
45 mg + 15 mg︰28 + 28 tablets/ box
60 mg + 30 mg︰28 + 28 tablets/ box
90 mg + 30 mg︰28 + 28 tablets/ box
*Please refer to the full prescribing information for details